CTIS2024-513835-25-00招募中1 期
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants with Dementia of the Alzheimer's Type - CTP3S1502HT6
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 375
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Participant and/or the participant’s LAR/caregiver can understand the written informed consent, provide signed and witnessed written informed consent, and agree to comply with protocol requirements prior to beginning any study procedures. 2. Is =50 years of age at Visit 1 and has a diagnosis of dementia of the Alzheimer’s type according to the NIA-AA 2011 criteria. Biomarkers will not be considered for eligibility. 3. Has onset of agitation symptoms at least 2 weeks prior to Visit 1. 4. Has confirmed agitation using the IPA Consensus Provisional Definition of Agitation in Cognitive Disorders. 5. Has an MRI or CT scan performed after onset of Alzheimer's disease symptoms and prior to randomization with findings consistent with the diagnosis of dementia of the Protocol CTP3S1502HT6, Page 49 and without any other clinically significant comorbid pathologies. 6. Has a score between 5 and 26 (both inclusive) on MMSE at Visit 1. 7. Has a clinically significant agitation/aggression (score of =4) as measured by the NPI-12 A/A at Visits 1 and 2. 8. Must be receiving treatment with stable doses of either a cholinesterase inhibitor or memantine or both for =3 months prior to Visit 1 and likely to be maintained on his/her current dose for the duration of the study. 9. Has no change to medications targeting behavioral manifestations of AD within 4 weeks prior to Visit 2. Lorazepam can be administered in a dose =1.5 mg/day and not to exceed 3 days in a 7-day period. Concomitant use of lorazepam must be recorded during visits. 10. Is permitted to use low-dose trazodone (up to 100 mg/day), eszopiclone, zolpidem, zopiclone, or zaleplon for nighttime management of insomnia. Insomnia medications must not be administered within 8 hours prior to the efficacy and/or safety assessments. 11. Is permitted to use anxiolytic medications (including benzodiazepine), and antidepressants (with the exclusion of tricyclic antidepressants), provided they have been on a stable dose for =4 weeks prior to Visit 1., 12. Is permitted to use supplements, medical foods, or pharmaceuticals specifically for the treatment of dementia, agitation, or sleep, containing omega-3 fatty acids, melatonin, vitamin B12, folate, or valerian root. However, the dose should be stable for =4 weeks prior to Visit 1 and must remain stable throughout the study. All stable supplements require review and approval by the medical monitor prior to randomization. 13. Has a person (ie, caregiver) who is qualified, willing, and able to provide accurate information regarding the participant's cognitive and functional abilities and will accompany the participant to study visits. The caregiver should have face-to-face contact with the participant for a minimum of approximately 8 hours per week spread over 3 to 5 days during the week. 14. Participants who are independent living, having in-home services, or living in assisted living or nursing homes. The participant can participate in this study if his/her caregiver ensures the administration of the study drug. 15. Has vision and hearing (corrected) sufficient to comply with the testing procedures. Both participant and caregiver must be able to read and understand the written information and have literacy skills to ensure compliance with the visit procedures. 16. Has no clinically significant abnormalities in general health, physical examination, neurological examination, ECG recording, or laboratory assessments. For ALT, AST, or TBL, clinically s
排除标准
- •1.Female participants who are pregnant or breast feeding. 2.Sexually active females of childbearing potential and male participants are not practicing two different methods of birth control with their partner. 3.Has history of confirmed COVID-19 within 3 months prior to Visit 1. 4.Has a diagnosis of dementia due to other non-Alzheimer disorders. 5.Has a history of stroke, documented TIAs, and/or pulmonary embolism within the last 12 months. 6.Has a diagnosis of schizophrenia, bipolar disorder, or current untreated/uncontrolled MDD or participants whose C-SDD scores are suggestive of probable depression (ie, scores =12) at Visits 1 or 2. 7.Has symptoms of agitation that are not secondary to AD. 8.Has symptoms of delirium or history of delirium within 1 month prior to Visit 1. 9.Has used or will continue to use MAOIs, linezolid, tricyclic antidepressants, or intravenous methylene blue within 14 days prior to Visit 1. 10.Has uncontrolled cardiac disease or hypertension. 11.All antipsychotics are prohibited and should be discontinued as appropriate. 12.Centrally acting anticholinergic medications are prohibited. 13.CYP3A4 substrates with narrow therapeutic index are prohibited and should be discontinued as appropriate. 14.Use of any medications/supplements/foods with known inhibitoryinducer effects on CYP3A4 should be discontinued from screening through EOT visit. 15.Use of herbal and dietary supplements that cause liver injury. Participants on stable use for at least 4 months prior to Visit 1 are allowed; however, herbal and dietary supplement dose changes and new herbal and dietary supplements are not allowed during the study., 16.Has a history or current evidence of QT prolongation syndrome, or Torsade de Pointes, as determined by ECG at Visits 1 or 2. 17.Has bradycardia (100 bpm) on the ECG at Visits 1 or 2. 18.Has uncontrolled type-1 or type-2 diabetes (defined as HbA1c >6.5% at Visit 1). 19.Has cancer, a malignant tumor, or has been treated for an active malignancy within the past 5 years. Participants with stable untreated prostate or cervical cancer, localized squamous cell cancer, or basal cell cancer are permitted. 20.Has clinically significant hepatic impairment. 21.Is treated or likely to require treatment during the study with any medications prohibited by the study protocol. 22.Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigator at Visits 1 or 2. 23.History of significant head injury, seizures, or any other unexplained, recurrent loss of consciousness for more than 15 minutes within 12 months of Visit 1. 24.Poorly controlled psychosis and other psychiatric disorder that, in the opinion of the investigator, would interfere with the participant’s ability to be compliant with the study protocol. 25.Known history of substance use disorder within 1 year prior to first dose of study drug, not including caffeine and nicotine. 26.Current implantable intracranial stimulator or history of intracranial ablation surgery. 27.Repetitive transcranial magnetic stimulation within 3 months prior to Visit 1. 28.Participation in experimental interventional treatments, including immunotherapy, for any aspects of AD in the past 6 months or 5 half-lives of the experimental drug product (whichever is longer), prior to the first dose of study drug. If the participant was on placebo arm of disease-modifying treatments, participation in t
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644